NCT01018017View on ClinicalTrials.gov

A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 3, 2010

Primary Completion Date

December 25, 2010

Study Completion Date

December 25, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.

DRUG

SRT2104

SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.

Trial Locations (1)

41460

GSK Investigational Site, Neuss

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01018017 - A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter